[1] Chowdhury MA,Xiubin Z,Wei H,et al. Cancer antigen-125 and ICAM-1 are together responsible for ascites in liver cirrhosis. Clin Lab,2014,60(4):653-658. [2] Dai H,Liu J,Liang Y,et al. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers. Respirology,2014,19(5):707-713. [3] Kayadibi H,Sertoglu E,Uyanik M. Evaluation of relationship between CA-125 levels and ascites in patients with liver cirrhosis. J Coll Physicians Surg Pak,2014,24(11):873. [4] Chang K,Lu SN. Incidence and associated risk factors of hepatocellular carcinoma in a dural hepatitis B and C virus endemir area;a surveillance study. Kaohsiung J Med Sci,2011,27(3):85-90. [5] Pissaia AJ,Bernard D,Scatton O,et al. Significance of serum tumor markers carcinoembryonic antigen,CA 19-9,CA 125,and CA 15-3 in pre-orthotopic liver transplantation evaluation. Transplant Proc,2013,41(2):682-684. [6] Trevisani FD,Intino PE,Morselli-Labate AM,et al. Serum alpha2 fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease:influence of HBsAg and anti HCV status. J Hepatol,2012,34(4):570-575. [7] Sorbye H,Dahl O. Carcinoembryonic antigen surge in metastatic colorectal cancer patients respongding to oxaliplatin combination chemotherapy:implications for tumor marker monitoring and guidelines.J Clin Oncol,2013,21(23):4466-4467. [8] Gazelle GS,Hunink MG,Kuntz KM,et al. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma:a state-transition Monte Carlo decision analysis. Ann Surg,2013,237(4):544-555. [9] Davies JR,Kirkham S,Svitacheva N,et al. MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells. Int J Biochem Cell Biol,2014,39: 1943-1954. [10] 陆再英,钟南山. 内科学. 1 版, 北京:人民卫生出版社,2008:437-453. [11] Wiesner R,Edwards E,Freeman R,et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology,2013,124(1):91-96. [12] Liu X,Chi X,Gong Q,et al. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma. PLoS One,2015,10(5):e0127518. [13] Yonemori K,Ando M,Shibata T,et al. Tumor marker analysis and verification of prognostic models in patients with cancer of unknown primary,receiving platinum based combination chemotherapy. J Cancer Res Clin Oncol,2016,132(10):635-642. [14] Smith RA, Cokkinides V,von Eschenbach AC, et al. American cancer society guidelines for the early detection of cancer. CA Cancer J Clin,2012,52(1):8-22. [15] Liu F,Kong X,Dou Q,et al. Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites. Ann Hepatol,2014,13(3):357-363. [16] 刘丹,朱清静,万青松,等. 清降钙素原联合C-反应蛋白检测诊断肝硬化并发自发性细菌性腹膜炎价值探讨. 实用肝脏病杂志,2015,18(1):80-81. [17] Qureshi MO,Dar FS,Khokhar N. Cancer antigen-125 as a marker of ascites in patients with liver cirrhosis. J Coll Physicians Surg Pak,2014,24(4):232-235. [18] 李佳红,付娜,牛学敏,等. 573例原发性肝癌病因及临床特点分析. 实用肝脏病杂志,2015,18(4):399-402. [19] Wang M,Devarajan K,Singal AG,et al. The Doylestown algorithm:A test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prev Res (Phila),2016,9(2):172-179. [20] Conti F, Dall'Agata M, Gramenzi A,et al. Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis. Biomark Med,2015,9(12):1343-1351. [21] 阮林松,许成新,陈世勇. 肝硬化患者血清及腹腔积液 CA199、CA125检测的意义. 放射免疫学杂志,2011,24(1):107-108. |